{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T05:05:38Z","timestamp":1785215138392,"version":"3.55.0"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Haploidentical donor hematopoietic cell transplantation (haplo-HCT) has become a preferred option for patients without HLA-matched donors, but it increases the risk of viral reactivations. Epstein\u2013Barr virus (EBV) and cytomegalovirus (CMV) are common viruses post-HCT, but limited data have been reported in the setting of haplo-HCT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a retrospective study enrolling acute leukemia patients who received haplo-HCT with myeloablative conditioning regimen employing ATG in our center from July 2014 to July 2017. All the patients enrolled were EBV-IgM and EBV-DNA negative but EBV-IgG positive, and so were their donors. The same went for CMV as well.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 602 patients were recruited consisting of 331 with acute myeloid leukemia (AML) and 271 with acute lymphoblastic leukemia (ALL). One-year cumulative incidences of EBV (22.9% \u00b1 2.4% vs. 27.4% \u00b1 2.8%, <jats:italic>P<\/jats:italic> = 0.169) and CMV (24.7% \u00b1 2.4% vs. 29.4% \u00b1 2.8%, <jats:italic>P<\/jats:italic> = 0.190) reactivation were comparable between AML and ALL. EBV and CMV were independent risk factors for each other. In the AML group, male recipients [HR = 1.275, 95% CI (1.001\u20131.624), <jats:italic>P<\/jats:italic> = 0.049] and acute graft-versus-host disease [HR = 1.592, 95% CI (1.001\u20132.533), <jats:italic>P<\/jats:italic> = 0.049] were independent risk factors for EBV reactivation and CMV reactivation, respectively. CMV rather than EBV reactivation was related to a trend of worsened treatment-related mortality (TRM) (15.6% \u00b1 0.1% vs. 10.2% \u00b1 0.0%, <jats:italic>P<\/jats:italic> = 0.067) and progression-free survival (PFS) (60.6% \u00b1 4.1% vs. 70.3% \u00b1 2.3%, <jats:italic>P<\/jats:italic> = 0.073), while significant impacts were revealed only in the subgroup analysis. CMV reactivation resulted in a remarkable inferior 2-year overall survival (OS) (64.2% \u00b1 5.7% vs. 77.6% \u00b1 3.2%, <jats:italic>P<\/jats:italic> = 0.038) and PFS (55.0% \u00b1 5.9% vs. 71.9% \u00b1 3.4%, <jats:italic>P<\/jats:italic> = 0.042) in ALL patients. On the other hand, in the EBV+\/CMV\u2212 subgroup, relapse was lower in ALL patients (8.2% \u00b1 0.2% vs. 32.4% \u00b1 0.8%, <jats:italic>P<\/jats:italic> = 0.010) compared with AML patients, which led to a superior 2-year OS (82.0% \u00b1 6.2% vs. 60.3% \u00b1 8.8%, <jats:italic>P<\/jats:italic> = 0.016) and PFS (74.5% \u00b1 7.0% vs. 57.5% \u00b1 8.4%, <jats:italic>P<\/jats:italic> = 0.036).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We concluded that EBV and CMV reactivations were frequent in acute leukemia patients after haplo-HCT, with possibly distinctive risk factors from HLA-matched HCT. There could be a potential interaction between EBV and CMV, but impacts on transplant outcomes remained complex.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcimb.2022.865170","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T07:06:51Z","timestamp":1652684811000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Features of Epstein\u2013Barr Virus and Cytomegalovirus Reactivation in Acute Leukemia Patients After Haplo-HCT With Myeloablative ATG-Containing Conditioning Regimen"],"prefix":"10.3389","volume":"12","author":[{"given":"Yuhua","family":"Ru","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiemei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziling","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aining","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiying","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengming","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengcheng","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suning","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Depei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.bbmt.2018.01.008","article-title":"Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium (HAPLO2016), San Diego, California, December 1, 2016","volume":"24","author":"Al Malki","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B2","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/sj.bmt.1705134","article-title":"High-Grade Cytomegalovirus Antigenemia After Hematopoietic Stem Cell Transplantation","volume":"36","author":"Asano-Mori","year":"2005","journal-title":"Bone Marrow Transplant."},{"key":"B3","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/ejh.12260","article-title":"Controlled Epstein\u2013Barr Virus Reactivation After Allogeneic Transplantation is Associated With Improved Survival","volume":"92","author":"Auger","year":"2014","journal-title":"Eur. J. Haematol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.bbmt.2008.10.023","article-title":"Donor and Recipient CMV Serostatus and Outcome of Pediatric Allogeneic HSCT for Acute Leukemia in the Era of CMV-Preemptive Therapy","volume":"15","author":"Behrendt","year":"2009","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B5","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.hemonc.2017.05.001","article-title":"Emerging Concepts in Cytomegalovirus Infection Following Hematopoietic Stem Cell Transplantation","volume":"10","author":"Camargo","year":"2017","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.bbmt.2017.12.796","article-title":"Comparison of Autologous Stem Cell Transplantation Versus Haploidentical Donor Stem Cell Transplantation for Favorable-and Intermediate-Risk Acute Myeloid Leukemia Patients in First Complete Remission","volume":"24","author":"Chen","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMra052638","article-title":"Hematopoietic Stem-Cell Transplantation","volume":"354","author":"Copelan","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1007\/s00277-021-04642-5","article-title":"Epstein\u2013Barr Virus and Cytomegalovirus Reactivation After Allogeneic Hematopoietic Cell Transplantation in Patients With non\u2013Hodgkin Lymphoma: The Prevalence and Impacts on Outcomes","volume":"100","author":"Ding","year":"2021","journal-title":"Ann. Hematol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1182\/blood-2010-08-304121","article-title":"Early Human Cytomegalovirus Replication After Transplantation is Associated With a Decreased Relapse Risk: Evidence for a Putative Virus-Versus-Leukemia Effect in Acute Myeloid Leukemia Patients","volume":"118","author":"Elmaagacli","year":"2011","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1007\/s00277-019-03742-7","article-title":"Risk Factors and Clinical Outcomes of Epstein\u2013Barr Virus DNAemia and Post-Transplant Lymphoproliferative Disorders After Haploidentical and Matched-Sibling PBSCT in Patients With Hematologic Malignancies","volume":"98","author":"Gao","year":"2019","journal-title":"Ann. Hematol."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.694588","article-title":"Therapeutic Vaccination of Hematopoietic Cell Transplantation Recipients Improves Protective CD8 T-Cell Immunotherapy of Cytomegalovirus Infection","volume":"12","author":"Gergely","year":"2021","journal-title":"Front. Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/bmt.2013.235","article-title":"High Burden of BK Virus-Associated Hemorrhagic Cystitis in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation","volume":"49","author":"Gilis","year":"2014","journal-title":"Bone Marrow Transplant."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1111\/ajt.15515","article-title":"Cytomegalovirus (CMV) Infection and Risk of Mortality in Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT): A Systematic Review, Meta-Analysis, and Meta-Regression Analysis","volume":"19","author":"Gim\u00e9nez","year":"2019","journal-title":"Am. J. Transplant."},{"key":"B14","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/sj.bmt.1705140","article-title":"Cause of Death After Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) in Early Leukaemias: An EBMT Analysis of Lethal Infectious Complications and Changes Over Calendar Time","volume":"36","author":"Gratwohl","year":"2005","journal-title":"Bone Marrow Transplant."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1182\/blood-2013-02-487074","article-title":"CMV Reactivation After Allogeneic HCT and Relapse Risk: Evidence for Early Protection in Acute Myeloid Leukemia","volume":"122","author":"Green","year":"2013","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/leu.2011.195","article-title":"High Epstein\u2013Barr Virus-Specific T-Cell Counts are Associated With Near-Zero Likelihood of Acute Myeloid Leukemia Relapse After Hematopoietic Cell Transplantation","volume":"26","author":"Hoegh-Petersen","year":"2012","journal-title":"Leukemia"},{"key":"B17","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B18","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.jcyt.2014.02.010","article-title":"The Clinical and Financial Burden of Pre-Emptive Management of Cytomegalovirus Disease After Allogeneic Stem Cell Transplantation\u2014Implications for Preventative Treatment Approaches","volume":"16","author":"Jain","year":"2014","journal-title":"Cytotherapy"},{"key":"B19","doi-asserted-by":"publisher","first-page":"287","DOI":"10.5114\/ceji.2016.63129","article-title":"Immune Recovery and the Risk of CMV\/EBV Reactivation in Children Post Allogeneic Haematopoietic Stem Cell Transplantation","volume":"41","author":"Janeczko","year":"2016","journal-title":"Central-European J. Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00277-014-2190-1","article-title":"Early CMV Replication and Subsequent Chronic GVHD Have a Significant Anti-Leukemic Effect After Allogeneic HSCT in Acute Myeloid Leukemia","volume":"94","author":"Jang","year":"2015","journal-title":"Ann. Hematol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/nrclinonc.2015.128","article-title":"Modern Approaches to HLA-Haploidentical Blood or Marrow Transplantation","volume":"13","author":"Kanakry","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/s11912-010-0113-4","article-title":"Haploidentical Transplantation for Leukemia","volume":"12","author":"Kanda","year":"2010","journal-title":"Curr. Oncol. Rep."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.805189","article-title":"Serotherapy as Graft-Versus-Host Disease Prophylaxis in Haematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukaemia","volume":"9","author":"Keogh","year":"2021","journal-title":"Front. Pediatr."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.3109\/10428194.2010.496015","article-title":"Post-Transplant Immune Reconstitution After Unrelated Allogeneic Stem Cell Transplant in Patients With Acute Myeloid Leukemia","volume":"51","author":"Klyuchnikov","year":"2010","journal-title":"Leuk. Lymphoma"},{"key":"B25","doi-asserted-by":"publisher","first-page":"4992","DOI":"10.1182\/blood-2008-09-178046","article-title":"Risk Factors for Lymphoproliferative Disorders After Allogeneic Hematopoietic Cell Transplantation","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1016\/j.bbmt.2015.06.001","article-title":"Sufficient Immunosuppression With Thymoglobulin Is Essential for a Successful Haplo-Myeloid Bridge in Haploidentical-Cord Blood Transplantation","volume":"21","author":"Lindemans","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B27","doi-asserted-by":"publisher","first-page":"30230","DOI":"10.18632\/oncotarget.8803","article-title":"Both High and Low Levels of Cellular Epstein-Barr Virus DNA in Blood Identify Failure After Hematologic Stem Cell Transplantation in Conjunction With Acute GVHD and Type of Conditioning","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1182\/blood.V116.21.533.533","article-title":"Analysis of Risk Factors Influencing Outcomes After Cord Blood Transplantation in Children With Juvenile Myelomonocytic Leukemia: A EUROCORD, EBMT, EWOG-MDS, CIBMTR Study","volume":"122","author":"Locatelli","year":"2013","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.bbmt.2013.10.003","article-title":"Protective Effect of Cytomegalovirus Reactivation on Relapse After Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients Is Influenced by Conditioning Regimen","volume":"20","author":"Manjappa","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B30","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jtct.2021.12.014","article-title":"Risk Factors for Early Cytomegalovirus Reactivation and Impact of Early Cytomegalovirus Reactivation on Clinical Outcomes After T Cell-Replete Haploidentical Transplantation With Post-Transplantation Cyclophosphamide","volume":"28","author":"Mariotti","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/sj.bmt.1703927","article-title":"Pre-Emptive Treatment of CMV DNAemia in Paediatric Stem Cell Transplantation: The Impact of Recipient and Donor CMV Serostatus on the Incidence of CMV Disease and CMV-Related Mortality","volume":"31","author":"Matthes-Martin","year":"2003","journal-title":"Bone Marrow Transplant."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13521","article-title":"Outcomes of Transplant Recipients Treated With Cidofovir for Resistant or Refractory Cytomegalovirus Infection","volume":"23","author":"Mehta Steinke","year":"2021","journal-title":"Transplant. Infect. Dis."},{"key":"B33","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/bmt.2008.150","article-title":"EBV Reactivation and Post Transplant Lymphoproliferative Disorders Following Allogeneic SCT","volume":"42","author":"Ocheni","year":"2008","journal-title":"Bone Marrow Transplant."},{"key":"B34","doi-asserted-by":"publisher","first-page":"242ra283","DOI":"10.1126\/scitranslmed.3008825","article-title":"Activity of Broad-Spectrum T Cells as Treatment for AdV, EBV, CMV, BKV, and HHV6 Infections After HSCT","volume":"6","author":"Papadopoulou","year":"2014","journal-title":"Sci. Trans. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/bmt.2014.312","article-title":"Hematopoietic SCT in Europe 2013: Recent Trends in the Use of Alternative Donors Showing More Haploidentical Donors But Fewer Cord Blood Transplants","volume":"50","author":"Passweg","year":"2015","journal-title":"Bone Marrow Transplant."},{"key":"B36","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/bmt.2017.34","article-title":"Use of Haploidentical Stem Cell Transplantation Continues to Increase: The 2015 European Society for Blood and Marrow Transplant Activity Survey Report","volume":"52","author":"Passweg","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"B37","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/leu.2011.26","article-title":"Features of Epstein-Barr Virus (EBV) Reactivation After Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation","volume":"25","author":"Peric","year":"2011","journal-title":"Leukemia"},{"key":"B38","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant."},{"key":"B39","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/pbc.25237","article-title":"Risk for CMV Reactivation in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation","volume":"62","author":"Qayed","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/bmt.2016.216","article-title":"Impact of Haploidentical Hematopoietic Cell Transplantation Conditioning Intensity on the Incidence and Severity of Post-Transplantation Viral Infections","volume":"51","author":"Raj","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"B41","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/ejh.13131","article-title":"Epstein-Barr Virus Post-Transplant Lymphoproliferative Disease (PTLD) After Hematopoietic Stem Cell Transplantation","volume":"101","author":"Ru","year":"2018","journal-title":"Eur. J. Haematol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1038\/s41409-020-0831-7","article-title":"Epstein\u2013Barr Virus Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation: Multifactorial Impact on Transplant Outcomes","volume":"55","author":"Ru","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"B43","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.bbmt.2015.01.004","article-title":"Impact of Serotherapy on Immune Reconstitution and Survival Outcomes After Stem Cell Transplantations in Children: Thymoglobulin Versus Alemtuzumab","volume":"21","author":"Storek","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B44","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/j.1399-3062.2009.00411.x","article-title":"Outcome of Treatment of Epstein\u2013Barr Virus-Related Post-Transplant Lymphoproliferative Disorder in Hematopoietic Stem Cell Recipients: A Comprehensive Review of Reported Cases","volume":"11","author":"Styczynski","year":"2009","journal-title":"Transplant. Infect. Dis."},{"key":"B45","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3324\/haematol.2016.144428","article-title":"Management of Epstein-Barr Virus Infections and Post-Transplant Lymphoproliferative Disorders in Patients After Allogeneic Hematopoietic Stem Cell Transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) Guidelines","volume":"101","author":"Styczynski","year":"2016","journal-title":"Haematologica"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.exphem.2006.05.021","article-title":"The Role of HLA Mismatch, Splenectomy and Recipient Epstein-Barr Virus Seronegativity as Risk Factors in Post-Transplant Lymphoproliferative Disorder Following Allogeneic Hematopoietic Stem Cell Transplantation","volume":"91","author":"Sundin","year":"2006","journal-title":"Haematologica"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/j.bbmt.2015.07.019","article-title":"Cytomegalovirus Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation Is Associated With a Reduced Risk of Relapse in Patients With Acute Myeloid Leukemia Who Survived to Day 100 After Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-Related Complication Working Group","volume":"21","author":"Takenaka","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early Cytomegalovirus Reactivation Remains Associated With Increased Transplant-Related Mortality in the Current Era: A CIBMTR Analysis","volume":"127","author":"Teira","year":"2016","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3324\/haematol.2013.087338","article-title":"Risk Factors for Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disease After Allogeneic Hematopoietic Stem Cell Transplantation","volume":"99","author":"Uhlin","year":"2014","journal-title":"Haematologica"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.bbmt.2007.06.006","article-title":"Cytomegalovirus Infection After Allogeneic Transplantation: Comparison of Cord Blood With Peripheral Blood and Marrow Graft Sources","volume":"13","author":"Walker","year":"2007","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B51","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1182\/blood-2014-03-563130","article-title":"Who Is the Best Donor for a Related HLA Haplotype-Mismatched Transplant","volume":"124","author":"Wang","year":"2014","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.2139\/ssrn.3798561","article-title":"Optimizing Antithymocyte Globulin Dosing in Haploidentical Hematopoietic Cell Transplantation: Long-Term Follow-Up of a Multicenter, Randomized Controlled Trial","volume":"66","author":"Wang","year":"2021","journal-title":"Sci. Bull."},{"key":"B53","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.bbmt.2014.11.674","article-title":"Impact of Serotherapy on Immune Reconstitution and Survival Outcomes After Stem Cell Transplantations in Children: Thymoglobulin Versus Alemtuzumab","volume":"21","author":"Willemsen","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-018-0564-x","article-title":"The Consensus on Indications, Conditioning Regimen, and Donor Selection of Allogeneic Hematopoietic Cell Transplantation for Hematological Diseases in China\u2014recommendations From the Chinese Society of Hematology","volume":"11","author":"Xu","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1038\/bmt.2017.59","article-title":"A Review of Hematopoietic Cell Transplantation in China: Data and Trends During 2008\u20132016","volume":"52","author":"Xu","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"B56","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1111\/j.1399-3046.2008.01084.x","article-title":"Cytomegalovirus Infection in Children Who Underwent Hematopoietic Stem Cell Transplantation at a Single Center: A Retrospective Study of the Risk Factors","volume":"13","author":"Yoon","year":"2009","journal-title":"Pediatr. Transplant."},{"key":"B57","doi-asserted-by":"publisher","first-page":"E491","DOI":"10.1111\/ctr.12172","article-title":"Epstein\u2013Barr Virus Reactivation in Allogeneic Stem Cell Transplantation Is Highly Related to Cytomegalovirus Reactivation","volume":"27","author":"Zallio","year":"2013","journal-title":"Clin. Transplant."},{"key":"B58","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/bmt.2013.223","article-title":"HLA-Haploidentical Hematopoietic SCT From Collateral Related Donors Without In Vitro T-Cell Depletion for Hematological Malignancies","volume":"49","author":"Zhang","year":"2014","journal-title":"Bone Marrow Transplant."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1007\/s00277-020-04014-5","article-title":"Comparison of ATG-Thymoglobulin With ATG-Fresenius for Epstein-Barr Virus Infections and Graft-Versus-Host-Disease in Patients With Hematological Malignances After Haploidentical Hematopoietic Stem Cell Transplantation: A Single-Center Experience","volume":"99","author":"Zhou","year":"2020","journal-title":"Ann. Hematol."},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13856","article-title":"Incidence, Risk Factors, and Clinical Outcomes Associated With Epstein-Barr Virus-DNAemia and Epstein-Barr Virus-Associated Disease in Patients After Haploidentical Allogeneic Stem Cell Transplantation: A Single-Center Study","volume":"34","author":"Zhou","year":"2020","journal-title":"Clin. Transplant."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.865170\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T07:06:55Z","timestamp":1652684815000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.865170\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,16]]},"references-count":60,"alternative-id":["10.3389\/fcimb.2022.865170"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2022.865170","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,16]]},"article-number":"865170"}}